论文部分内容阅读
对同期住院的 12 0名经确诊的慢性阻塞性肺气肿病人 ,随机分为观察组 6 0例 ,采用肺得康微粉吸入 ,一天 2次 ,同时进行肺功能锻炼 ,每天 2～ 3次 ,每次 10～ 2 0分钟 ,唯尔本肌注 2ml,隔日 1次 ,上述药物连用半年 ,对照组氨茶碱 ,喘康速气雾剂及必可酮气雾剂同时也进行肺功能锻炼 ,于治疗前后观察症状 ,体征、肺功能及免疫球蛋白变化 ,半年后评价疗效并进行统计学分析 ,结果观察组显效 2 6例 (43.4% ) ;好转 30例 (5 0 % ) ) ;无效 4例 (6 .6 % )。对照组显效 12例 (2 0 % ) ,好转 16例 (2 6 .6 % ) ,无效 32例 (5 3.3% )。观察组肺功能FVC、FEV1、MMEF及免疫球蛋白IgG在治疗前后有显著改变 ,且与对照组比较 P <0 .0 1。结果提示肺得康、唯尔本联合治疗慢性阻塞性肺气肿病人不但改善临床症状而且缓解了肺气肿进一步发展 ,提高了患者的抗病能力 ,减少了呼吸道感染的次数 ,且具有远期治疗效果。
Of the 120 hospitalized patients with chronic obstructive pulmonary disease over the same period were randomly divided into observation group of 60 patients with Pulmicort powder inhalation, 2 times a day, at the same time lung function exercise, 2 or 3 times a day, Each 10 ~ 2 0 minutes, Wolverine intramuscular injection of 2ml, every other day 1, the drug used in combination for six months, the control group aminophylline, asthma aerosol and ketoconazole aerosol also also lung function training, The symptoms, signs, lung function and immunoglobulin changes were observed before and after treatment. After six months, the curative effect was evaluated and statistically analyzed. The results showed that the observation group was markedly effective in 26 cases (43.4%); improvement in 30 cases (50%); Example (6.6%). The control group was significantly improved in 12 cases (20%), improvement in 16 cases (26.6%), 32 cases (33.3%). The lung function FVC, FEV1, MMEF and immunoglobulin IgG in the observation group had significant changes before and after treatment, and P <0.01 compared with the control group. The results suggest that lung Health, Wolben combined treatment of patients with chronic obstructive pulmonary disease not only improve clinical symptoms but also to alleviate the further development of emphysema, improve patient resistance to disease, reduce the number of respiratory infections, and have a long-term treatment effect.